EXITHERA PHARMACEUTICALS
ExIthera Pharmaceuticals is a developer of an early-stage biotechnology platform used to develop small-molecule pharmaceuticals. The company's stroke prevention and antithrombosis drugs are based on the unique pathophysiological role of Factor XI in the initiation of intravascular thrombi without causing undue bleeding. It focuses on developing stroke prevention and anti-thrombosis drugs based on Factor XI, which has a pathophysiological role in the initiation of intravascular thrombi without causing undue bleeding, enabling physicians to treat serious consequences, including venous thromboembolism, deep vein thrombosis, stroke, and heart attack.
EXITHERA PHARMACEUTICALS
Industry:
Biotechnology Genetics Health Care Medical Pharmaceutical
Founded:
2012-01-01
Address:
Westborough, Massachusetts, United States
Country:
United States
Website Url:
http://www.exithera.com
Total Employee:
1+
Status:
Active
Contact:
+1 508 983 1436
Email Addresses:
[email protected]
Total Funding:
18 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Nginx Sitelinks Search Box
Similar Organizations
Adastra Pharmaceuticals
Adastra Pharmaceuticals provides responsible solutions to advance patient care in oncology.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Current Advisors List
Current Employees Featured
Founder
Investors List
Schooner Capital
Schooner Capital investment in Venture Round - eXIthera Pharmaceuticals
Schooner Capital
Schooner Capital investment in Series B - eXIthera Pharmaceuticals
Schooner Capital
Schooner Capital investment in Venture Round - eXIthera Pharmaceuticals
Access BridgeGap Ventures
Access BridgeGap Ventures investment in Series A - eXIthera Pharmaceuticals
Official Site Inspections
http://www.exithera.com
- Host name: 50.243.209.35.bc.googleusercontent.com
- IP address: 35.209.243.50
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "eXIthera Pharmaceuticals"
eXIthera Pharmaceuticals - Crunchbase Company Profile & Funding
ExIthera Pharmaceuticals is a developer of an early-stage biotechnology platform used to develop small-molecule pharmaceuticals. The company's stroke prevention and antithrombosis drugs …See details»
eXIthera Pharmaceuticals Company Profile 2024: Valuation, …
EXIthera Pharmaceuticals General Information Description. Developer of novel, potent, and selective small molecule inhibitors designed to prevent thrombosis with limited risk for bleeding …See details»
eXIthera Pharmaceuticals, Inc. - Drug pipelines, Patents, Clinical ...
Jul 1, 2023 Explore eXIthera Pharmaceuticals, Inc. with its drug pipeline, therapeutic area, technology platform, 2 clinical trials, 2 news, and 1 literature, Technology Platform ...See details»
EXITHERA PHARMACEUTICALS, INC - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for EXITHERA PHARMACEUTICALS, INC of Westborough, MA. Get the latest business insights from Dun & …See details»
eXIthera Pharmaceuticals, Inc. (eXIthera Pharmaceuticals, Inc.) - 药 …
About eXIthera eXIthera is a clinical-stage biotech company developing small molecule inhibitors of Factor XIa, which offer the potential of thrombosis prevention without the bleeding liabilities …See details»
eXIthera Pharmaceuticals - Products, Competitors, Financials, …
EXIthera Appoints Michael Kurz, Ph.D., to Leadership Team. Jun 25, 2019. Dr. Kurz joins eXIthera as the Vice President of Translational Medicine and Medical Affairs News provided …See details»
eXIthera Pharmaceuticals - Funding, Financials, Valuation & Investors
Their latest funding was raised on Aug 10, 2017 from a Venture - Series Unknown round. eXIthera Pharmaceuticals is funded by 2 investors. Schooner Capital and Schooner Capital are the …See details»
eXIthera Pharmaceuticals - Overview, News & Similar companies ...
Mar 2, 2021 eXIthera is a clinical-stage biotech company developing small molecule inhibitors of Factor XIa which offer the potential of thrombosis prevention without the bleeding liabilities …See details»
eXIthera Pharmaceuticals Company Profile - Office Locations ...
EXIthera Pharmaceuticals is a biotech company specializing in Factor XIa inhibition, the target for anticoagulation, preventing thrombosis without an increased risk in bleeding. Its drug …See details»
eXIthera Pharmaceuticals - Crunchbase
ExIthera Pharmaceuticals supports the creation of antithrombotic and stroke prevention medications.See details»
eXIthera Pharmaceuticals - VentureRadar
EXIthera is the leader in Factor XIa inhibition, the ideal target for anticoagulation, preventing thrombosis without an increased risk in bleeding. eXIthera’s drug candidates are small …See details»
eXIthera - Advisory and Director Team - The Org
The Advisory and Director Team at eXIthera provides strategic guidance and oversight to ensure the company's focus on Factor XIa inhibition is effectively translated into groundbreaking …See details»
eXIthera Appoints Michael Kurz, Ph.D., to Leadership Team
Jun 25, 2019 eXIthera is a clinical-stage biotech company developing small molecule inhibitors of Factor XIa which offer the potential of thrombosis prevention without the bleeding liabilities …See details»
In the News Archives - eXIthera
Oct 1, 2020 Every emerging biopharmaceutical company has an interesting story that describes how they overcame major startup challenges, including study design, funding, and drug …See details»
ForbesBOOKS interview with Dr. Neil Hayward - eXIthera
Neil Hayward, Ph.D. is CEO of eXIthera; eXIthera is the leader in Factor XIa inhibition, the ideal target for anticoagulation. Their drug candidates are small molecules that prevent thrombosis …See details»
eXIthera Pharmaceuticals - Contacts, Employees, Board Members, …
Organization. eXIthera Pharmaceuticals . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. ... eXIthera Pharmaceuticals has …See details»
eXIthera Announces Publication of EP-7041 Data Demonstrating …
Sep 17, 2020 Clinical and preclinical data published in Critical Care Explorations demonstrate that EP-7041 has the ability to inhibit ECMO-related thrombosis while minimizing the risk of …See details»
eXIthera Pharmaceuticals Announces FDA Acceptance of IND …
Mar 3, 2021 eXIthera is a clinical-stage biotech company developing small molecule inhibitors of Factor XIa, which offer the potential of thrombosis prevention without the bleeding liabilities …See details»
eXIthera Presents Clinical Data on Novel Small Molecule
Nov 13, 2017 The Company is advancing two small molecule programs to inhibit Factor XIa, a clinically validated target for the prevention of thrombosis. eXIthera's lead product, EP-7041, is …See details»
eXIthera Announces Publication of EP-7041 Data Demonstrating …
Sep 17, 2020 eXIthera is a clinical-stage biotech company developing small molecule inhibitors of Factor XIa which offer the potential of thrombosis prevention without the bleeding liabilities …See details»